Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.

Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M.

Stem Cells. 2012 Oct;30(10):2100-13. doi: 10.1002/stem.1193.

2.

Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.

Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD.

Clin Cancer Res. 2014 Aug 1;20(15):4154-66. doi: 10.1158/1078-0432.CCR-13-3292. Epub 2014 Jun 6.

3.

Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.

Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW.

Stem Cells. 2011 Jan;29(1):32-45. doi: 10.1002/stem.563.

4.

Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.

Li SY, Sun R, Wang HX, Shen S, Liu Y, Du XJ, Zhu YH, Jun W.

J Control Release. 2015 May 10;205:7-14. doi: 10.1016/j.jconrel.2014.11.011. Epub 2014 Nov 15.

PMID:
25445694
5.

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.

Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R.

Melanoma Res. 2015 Apr;25(2):138-48. doi: 10.1097/CMR.0000000000000144.

PMID:
25643237
6.

The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.

Wouters J, Stas M, Gremeaux L, Govaere O, Van den Broeck A, Maes H, Agostinis P, Roskams T, van den Oord JJ, Vankelecom H.

PLoS One. 2013 Oct 3;8(10):e76550. doi: 10.1371/journal.pone.0076550. eCollection 2013.

7.

Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.

Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, Fukusumi T, Sakai D, Kudo T, Haraguchi N, Satoh T, Takiguchi S, Mori M, Doki Y, Ishii H.

Int J Oncol. 2013 Apr;42(4):1437-42. doi: 10.3892/ijo.2013.1837. Epub 2013 Feb 22.

PMID:
23440340
8.

Selection of tumorigenic melanoma cells using ALDH.

Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, Leong SP, Smith JE, Ghadially R.

J Invest Dermatol. 2010 Dec;130(12):2799-808. doi: 10.1038/jid.2010.237. Epub 2010 Aug 26.

9.

Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells.

Lin JJ, Huang CS, Yu J, Liao GS, Lien HC, Hung JT, Lin RJ, Chou FP, Yeh KT, Yu AL.

Breast Cancer Res. 2014 Mar 26;16(2):R29. doi: 10.1186/bcr3631.

10.

Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity.

Wang L, Park P, Zhang H, La Marca F, Lin CY.

Int J Cancer. 2011 Jan 15;128(2):294-303. doi: 10.1002/ijc.25331. Epub 2010 Mar 22.

11.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

12.

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.

Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD.

Cancer Res. 2010 Dec 1;70(23):9937-48. doi: 10.1158/0008-5472.CAN-10-0881. Epub 2010 Nov 30.

13.
14.

BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.

Wang L, Park P, La Marca F, Than KD, Lin CY.

J Cancer Res Clin Oncol. 2015 Jun;141(6):1013-24. doi: 10.1007/s00432-014-1883-0. Epub 2014 Nov 28.

PMID:
25431339
15.

The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.

Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC, Regad T.

Cell Death Dis. 2014 Feb 13;5:e1061. doi: 10.1038/cddis.2014.29.

16.

Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling.

Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA.

Stem Cells. 2012 Nov;30(11):2366-77. doi: 10.1002/stem.1219.

17.

The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.

Januchowski R, Wojtowicz K, Zabel M.

Biomed Pharmacother. 2013 Sep;67(7):669-80. doi: 10.1016/j.biopha.2013.04.005. Epub 2013 May 9. Review.

PMID:
23721823
18.

The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.

Li D, Zhang T, Gu W, Li P, Cheng X, Tong T, Wang W.

Oncol Rep. 2015 May;33(5):2291-8. doi: 10.3892/or.2015.3842. Epub 2015 Mar 9.

PMID:
25760144
19.

Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.

Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L, Stecca B.

Stem Cells. 2012 Sep;30(9):1808-18. doi: 10.1002/stem.1160.

20.

Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S.

PLoS One. 2010 Nov 3;5(11):e13831. doi: 10.1371/journal.pone.0013831.

Items per page

Supplemental Content

Write to the Help Desk